MCM2 and melanoma: In melanoma cells, a sustained CDC7 expression and associated MCM2–7 activation were observed in vemurafenib-resistant cells, and the CDC7 inhibitor TAK-931 was suggested as a therapeutic option for vemurafenib-resistant melanoma cells [39].